


**Claims:**


1. Use of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.
2. Use according to claim 1, wherein the agent is capable of being bound by a ligand binding site present on SAP.
3. Use according to claim 2, wherein the agent comprises a plurality of ligands covalently co-linked so as to form a complex with SAP and a second protein, wherein at least two of the ligands are the same or different, one of which is capable of being bound by a ligand binding site present on SAP and another is capable of being bound by a ligand binding site present on the second protein.
4. Use according to claim 3, wherein the second protein is SAP.
5. Use according to claim 3 or claim 4, wherein the ligands are covalently co-linked by a linker.
6. Use according to claim 5, wherein the linker comprises a linear or branched hydrocarbylene in which one or more of the carbon atoms thereof is optionally substituted by a heteroatom.
7. Use according to any preceding claim, wherein the agent has two ligands.
8. Use according to claim 6, wherein the agent has the general structure:  
Ligand – linker – Ligand
9. Use according to any of claims 3 to 8, wherein the ligand capable of being bound by a ligand binding site on SAP comprises a substituted or unsubstituted D-proline or stereoanalogue thereof.

10. Use according to claim 9, wherein the agent is a D-proline of the formula



wherein

R is



the group

$R^1$  is hydrogen or halogen;

X is  $-(CH_2)_n-$ ;  $-CH(R^2)(CH_2)_n-$ ;  $-CH_2O(CH_2)_n-$ ;  $-CH_2NH-$ ; benzyl,  $-C(R^2)=CH-$ ;  $-CH_2CH(OH)-$ ; or thiazol-2,5-diyl;

Y is  $-S-S-$ ;  $-(CH_2)_n-$ ;  $-O-$ ;  $-NH-$ ;  $-N(R^2)-$ ;  $-CH=CH-$ ;  $-NHC(O)NH-$ ;

$N(R^2)C(O)N(R^2)-$ ;  $-N[CH_2C_6H_3(OCH_3)_2]-$ ;  $-N(CH_2C_6H_5)-$ ;

$-N(CH_2C_6H_5)C(O)N(CH_2C_6H_5)-$ ;  $-N(\text{alkoxyalkyl})-$ ;

$N(\text{cycloalkyl-methyl})-$ ; 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-

cyclohexyl; 1,2-naphthyl; 1,4-naphthyl; 1,5-naphthyl; 1,6-naphthyl;

biphenyl; or 1,2-phenylene, 1,3-phenylene and 1,4-phenylene, wherein the phenylene groups are optionally substituted by 1 - 4 substituents, selected from

halogen, lower alkyl, lower alkoxy, hydroxy, carboxy,  $-COO$ -lower alkyl, nitrilo,

5-tetrazol, (2-carboxylic acid pyrrolidin-1-yl)-2-oxo-ethoxy, N-

hydroxycarbamimidoyl, 5-oxo[1,2,4]oxadiazolyl, 2-oxo-

[1,2,3,5]oxathiadiazolyl, 5-thioxo[1,2,4]oxadiazolyl and  
5-tert-butylsulfanyl-[1,2,4]oxadiazolyl;  
X' is  $-(CH_2)_n-$ ;  $-(CH_2)_nCH(R^2)-$ ;  $-(CH_2)_nOCH_2-$ ;  $-NHCH_2-$ ;  
benzyl,  $-CH=C(R^2)-$ ;  $-CH(OH)CH_2$ ; or thiazol-2,5-diyl;  
 $R^2$  is lower alkyl, lower alkoxy or benzyl and  
n is 0-3,  
or a pharmaceutically acceptable salt or mono- or diester thereof.

11. Use according to claim 10, wherein the D-proline is  
(R)-1-[6-(R)-2-Carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid  
or a pharmaceutically acceptable salt or mono- or diester thereof.

12. Use according to claim 2, wherein the agent comprises a substituted or  
unsubstituted D-proline or stereoanalogue thereof.

13. A method for treatment or prevention of osteoarthritis in a subject, which  
comprises administering to the subject a therapeutically effective amount of a  
medicament comprising an agent capable of inhibiting SAP ligand binding activity or  
depleting SAP from the plasma of the subject.